Publication | Open Access
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
23
Citations
38
References
2021
Year
LA-induced immune antitumour activity through DC cross-activation with CD8<sup>+</sup> T and NK cells, which demonstrated proof-of-concept evidence for the capability and safety of a novel therapeutic tumour vaccine.
| Year | Citations | |
|---|---|---|
Page 1
Page 1